Member Info for Hugh-Jarse

"We are on track to deliver full year 2018 results in line with our expectations, and subject to shareholder approval, we reiterate our commitment to return £600 million by way of total dividend to shareholders in 2019, a 20% increase on 2018."

Dividends:

"The Board currently intends to propose a total dividend of 15.07 eurocents per share for the current financial year, in-line with the FY18 dividend, with an interim dividend of 4.84 eurocents (also stable YoY). The Board will consider growing the dividend per share over the long-term, once the Group's financial leverage has reduced towards the lower end of the revised target range of 2.5x-3.0x net debt / EBITDA. "

https://www.investegate.co.uk/vodafone-group-plc--vod-/rns/half-year-report/201811130700131233H/

Try:
v.o.x.m.a.r.k.e.t.s.c.o.u.k

**************************************/articles/why-you-need-to-follow-motif-bio-s-fight-against-superbugs-c00f81f/

"Sale of T3 Project and creation of New Exploration Joint Venture with MOD Resources"

https://www.investegate.co.uk/metal-tiger-plc--mtr-/bus/sale-of-t3-project-and-creation-of-new-exploration-joint-venture-with-mod-resources/20181101070000Z8587/

"Key Saudi Exploration Licence Issued"

https://www.investegate.co.uk/kefi-minerals-plc--kefi-/rns/key-saudi-exploration-licence-issued/201811010700049498F/

https://www.investegate.co.uk/polo-resources-ltd--pol-/rns/celamin-holdings-nl---investment-update/201810310700238275F/

".....a longstanding KEFI institutional shareholder (the "Lender") who holds under 3% and therefore does not have a disclosable interest."

Wonder if the second £2m will take him over the threshold.

Cheers Ivy, was hoping you'd be first to reply.

I had noticed MRSA, wound infection etc were missing from
the picture.
Also progress in months and years is well behind us, think of
a number then double it. Hugh.

Serious question and happy to be torn to bits, as significant part of my PF is MTFB.

https://www.msn.com/en-gb/news/techandscience/antibiotic-trojan-horse-could-defeat-superbugs-causing-global-medical-crisis-trial-finds/ar-BBOUlUm?ocid=spartandhp

"CELAMIN HOLDINGS - INVESTMENT UPDATE"

https://www.investegate.co.uk/polo-resources-ltd--pol-/rns/celamin-holdings---investment-update/201810081529473287D/

* 2nd and corrected version

https://www.investegate.co.uk/thor-mining-plc--thr-/rns/appendix-3b/201810050943311165D/

........"A post-hoc analysis was conducted on the pooled data from the REVIVE-1 and REVIVE-2 Phase 3 trials to evaluate the safety and efficacy of iclaprim compared to vancomycin, the current standard of care, in treating wound infections, including surgical site infections. Fifty percent (602/1198) of the REVIVE intent-to-treat (ITT) population had wound infections. Iclaprim achieved non-inferiority to vancomycin, based on early clinical response at the early time point in the subgroup of patients with wound infections. Iclaprim and vancomycin had similar adverse event profiles in patients with wound infections. Two vancomycin-treated patients and no iclaprim-treated patients had serum creatinine levels ≥3 x upper limit of normal, indicating potential nephrotoxicity, a toxicity known to occur with vancomycin administration."....

"Motif Bio Presents New Iclaprim Data at IDWeek"

https://www.investegate.co.uk/motif-bio-plc--mtfb-/rns/motif-bio-presents-new-iclaprim-data-at-idweek/201810030801017249C/

"Non-exclusive distribution agreement for SlimBiome"

https://www.investegate.co.uk/optibiotix-health--opti-/rns/non-exclusive-distribution-agreement-for-slimbiome/201810030700027468C/

A 3 year agreement.
"This agreement is the first covering the CholBiome® range following our recent launch online in the UK and is the first step in our strategy to expand OptiBiotix's sales of CholBiome® own label products into the European market. Bulgaria has some of the highest mortality rates in Europe caused by cardiovascular disease accounting for up to 64% of all deaths (WHO). CholBiome® products containing LPLDL® have a unique ability to reduce both cholesterol and blood pressure providing a clinically proven natural product to help reduce these cardiovascular risk factors in countries with a high prevalence of these conditions."

As usual OPTI keeping 'stum' as to the identity of the Bulgarian company.

"Distribution agreement for CholBiome®"

https://www.investegate.co.uk/optibiotix-health--opti-/rns/distribution-agreement-for-cholbiome-/201809260700029053B/

"Successful Fundraising of £5.2m via PrimaryBid"

Issue of x3,554,893 extra shares, first day of dealing
08:00Hrs Thu 27Sep.

https://www.investegate.co.uk/versarien-plc--vrs-/rns/successful-fundraising-of--5-2m-via-primarybid/201809240700116312B/

TR-1 by Spreadex Ltd, St Albans.

https://www.investegate.co.uk/premaitha-health-plc--nipt-/rns/holding-s--in-company/201809210700044799B/